Cardio Diagnostics Holdings, Inc. (CDIO) has announced two new strategic partnerships that broaden its geographic footprint and deepen its community engagement. On January 7 2026 the company entered into a joint venture with Aimil Ltd. and Dr. Lal PathLabs Limited to launch its PrecisionCHD™ epigenetics‑based cardiovascular risk test across India’s largest private laboratory network. The following day, on January 6 2026, CDIO partnered with the Southdale YMCA in Minnesota to bring its PrecisionCHD™ and Epi+Gen CHD™ tests to local residents through educational events, a heart‑health fair, and on‑site blood‑sample collection.
The India deal marks CDIO’s first expansion outside the United States and taps a market where coronary heart disease (CHD) prevalence reaches 13% in urban areas and 7.4% in rural regions. By leveraging Dr. Lal PathLabs’ 290 laboratories and 300+ MD pathologists, the company can deliver its test nationwide, positioning it to capture a share of a population that develops heart disease nearly a decade earlier than Western cohorts. The partnership also aligns with CDIO’s AI‑driven, epigenetics‑based platform, which can detect both obstructive and non‑obstructive CHD, including INOCA and MINOCA, giving it a competitive edge over traditional angiography.
The Minnesota partnership extends CDIO’s community‑based outreach strategy. The Southdale YMCA will host educational sessions and a heart‑health fair on February 25 2026, with January 26 2026 events already scheduled. Members receive discounted test pricing and on‑site sample collection, creating a low‑barrier entry point for early detection. This initiative follows a similar partnership with the YMCA of East Tennessee, underscoring CDIO’s focus on building a broad customer base beyond its original anchor program.
Financially, CDIO has faced liquidity and revenue‑growth challenges, reporting a Q3 2025 revenue of $0.01 million and a net loss of $5.03 million. The new partnerships are expected to generate fresh revenue streams and accelerate the company’s path to scale, addressing the shortfall highlighted in recent disclosures. By entering a high‑growth market and expanding community access, CDIO aims to diversify its revenue base and reduce reliance on the U.S. market.
Investors reacted positively to the announcements, with CDIO’s stock surging 9.3% in pre‑market trading after the India partnership and a 29.61% jump following the Minnesota deal. Management emphasized the strategic importance of these deals: CEO Dr. Meesha Dogan said the India partnership “democratizes access to advanced cardiovascular diagnostics” and the YMCA partnership “provides more individuals an opportunity to be proactive about their heart health.”
The partnerships signal a clear shift toward scaling the PrecisionCHD™ platform globally while strengthening local market penetration through community channels. If the company can translate these agreements into robust test volumes, it could reverse its recent revenue decline and improve cash flow, positioning CDIO for a more sustainable growth trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.